18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era (2014)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- Subjects: LINFOMA (ETIOLOGIA); FÁRMACOS IMUNOSSUPRESSORES; IMUNOHISTOQUÍMICA; PROGNÓSTICO
- Language: Inglês
- Imprenta:
- Source:
- Título: Blood
- Volume/Número/Paginação/Ano: v. 124, n. 21, res. 3051, suppl, 2014
- Conference titles: Annual Meeting and Exposition / ASH
-
ABNT
LAGE, Luís Alberto de Pádua Covas et al. 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://ash.confex.com/ash/2014/webprogram/Paper69673.html. Acesso em: 11 fev. 2026. , 2014 -
APA
Lage, L. A. de P. C., Hallack Neto, A. E., Santucci, R., Costa, R. O., Siqueira, S., Paula, H. M. de, & Pereira, J. (2014). 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://ash.confex.com/ash/2014/webprogram/Paper69673.html -
NLM
Lage LA de PC, Hallack Neto AE, Santucci R, Costa RO, Siqueira S, Paula HM de, Pereira J. 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era [Internet]. Blood. 2014 ; 124( 21):[citado 2026 fev. 11 ] Available from: https://ash.confex.com/ash/2014/webprogram/Paper69673.html -
Vancouver
Lage LA de PC, Hallack Neto AE, Santucci R, Costa RO, Siqueira S, Paula HM de, Pereira J. 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era [Internet]. Blood. 2014 ; 124( 21):[citado 2026 fev. 11 ] Available from: https://ash.confex.com/ash/2014/webprogram/Paper69673.html - Adult T-Cell Leukemia/Lymphoma: A Clinical and Epidemiological Analysis at the Medicine School of Sao Paulo University
- How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation
- Radiographic patterns of multiple myeloma in the jawbones of patients treated with intravenous bisphosphonates
- GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms
- Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
- Panoramic and skull imaging may aid in the identification of multiple myeloma lesions
- Estudo de células precuroras em leucemias agudas: identificação e fator de prognóstico das proteínas Bcl-2, Bax e CD95/Fas/APO-1
- Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study
- Immune reconstitution inflammatory syndrome-associated lymphoma: a retrospective Brazilian cohort
- Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
